SCHEMBL6090711

SCHEMBL6090711

CCC(CC)(c1ccc2c(c1)OCCO2)c1c[nH]c2c(NS(=O)(=O)CC)cccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 6/20 0.42
PGR P06401 6/20 0.42
NR3C2 P08235 6/20 0.42
AR P10275 6/20 0.42
MAPT P10636 1/20 0.37
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
ALDH1A1 P00352 4/20 0.36
PARP14 Q460N5 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
ADRA2A P08913 1/20 0.34
IDO1 P14902 1/20 0.34
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091030 0.92 NR3C1 (0.51) NR3C1PGRNR3C2ARKDM4E
SCHEMBL6089177 0.86 NR3C1 (0.51) NR3C1PGRNR3C2ARMAPT
SCHEMBL6088800 0.82 NR3C1 (0.48) NR3C1PGRNR3C2ARKDM4E
SCHEMBL8325668 0.77 NR3C1 (0.69) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL6090405 0.77 NR3C1 (0.69) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL6089499 0.77 NR3C1 (0.49) NR3C1PGRNR3C2AR
SCHEMBL6091165 0.75 NR3C1 (0.53) NR3C1PGRNR3C2AR
SCHEMBL6245404 0.74 TAAR1 (0.33) SMN1; SMN2TSHRKMT2ALMNAHTT
SCHEMBL6091273 0.74 NR3C2 (0.54) NR3C1PGRNR3C2ARKDM4E
SCHEMBL6090257 0.74 NR3C1 (0.67) NR3C1PGRNR3C2ARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors ELI LILLY AND COMPANY (US) 2006-10-19 US disclosed
EP-1597254-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS Eli Lilly and Company (US) 2005-11-23 EP disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors NR3C2, NR5A1, MC2R NR3C1 4/4885PGR 148/4885NR3C2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.